Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapamycin in ADPKD
NCT00286156Phase 2Completed
- Sponsor
- Cleveland Clinic
- Start
- Oct 2006
- Primary completion
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sirolimus in autosomal dominant polycystic kidney disease (ADPKD) (3 arms), sponsored by Cleveland Clinic. Primary endpoint: Change in iothalamate Glomerular Filtration Rate at 12 months. Started Oct 2006; status: completed.
02
Drugs
sirolimus
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT00286156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00286156.